Residency · Residency · Allergy Immunology

Vaccine Allergy and Immunization in the Immunocompromised

Vaccine Allergy

Epidemiology

True vaccine allergy is a rare phenomenon, with anaphylaxis occurring at a rate of approximately 1 to 2 per million vaccine doses administered. The vast majority of adverse events following vaccination are not allergic in nature; vasovagal syncope, local injection site reactions, and coincidental illnesses temporally associated with vaccination account for the overwhelming majority of reported events. When genuine allergic reactions to vaccines do occur, they may be directed against the active antigenic component, against excipients used as stabilizers, preservatives, or emulsifiers, against culture medium proteins retained in trace amounts during manufacturing, or against residual processing agents.

Vaccine Excipients and Allergenic Potential

Gelatin is a stabilizer present in several vaccines including MMR, varicella, zoster, some influenza formulations, and Japanese encephalitis vaccine. It is the most commonly identified excipient allergen responsible for vaccine-associated anaphylaxis. Patients with a prior allergic reaction to a gelatin-containing vaccine should undergo skin prick testing and/or specific IgE measurement for gelatin before receiving subsequent gelatin-containing vaccines.

Egg protein (ovalbumin) is present in vaccines grown in embryonated eggs, most notably influenza vaccines, which contain less than 1 microgram of ovalbumin per dose in most inactivated formulations. Yellow fever vaccine, also produced in embryonated eggs, contains significantly more egg protein and carries the highest risk among egg-containing vaccines. A critical clinical distinction concerns the MMR vaccine, which is grown in chick embryo fibroblasts rather than eggs and contains negligible egg protein; it is therefore safe for administration to egg-allergic individuals. The current ACIP and AAAAI guidance states unequivocally that egg-allergic individuals may receive any influenza vaccine without special precautions, regardless of the severity of their egg allergy. This recommendation is based on multiple large studies demonstrating that the rate of anaphylaxis following influenza vaccination is identical in egg-allergic and non-egg-allergic individuals. There is no need for egg-free formulations and no need for prolonged observation beyond the standard recommended period. Yellow fever vaccine, in contrast, does contain significant egg protein, and egg-allergic patients should undergo skin testing and graded challenge before administration.

Polyethylene glycol (PEG, also known as macrogol) is an excipient in the mRNA COVID-19 vaccines manufactured by Pfizer and Moderna, and is also found in numerous medications including colonoscopy preparations and laxatives. PEG has been identified as a rare but recognized cause of anaphylaxis to mRNA vaccines. Structural similarity between PEG and polysorbate 80, both being polyether compounds, raises the possibility of cross-reactivity. Polysorbate 80 (Tween 80) is present in many other vaccines, including the J&J COVID-19 vaccine, influenza, DTaP, and HPV vaccines. Evaluation of patients with suspected PEG allergy includes skin testing with PEG 3350 solution and polysorbate 80, followed by graded vaccine challenge if skin testing is negative.

Latex from natural rubber may be present in vial stoppers or syringe plungers of some vaccines, though most modern vaccine products are latex-free; verification through the package insert is recommended for latex-allergic patients. Yeast (Saccharomyces cerevisiae) is used in the production of recombinant hepatitis B and HPV vaccines, though true yeast allergy is exceedingly rare. Neomycin and streptomycin are present in trace amounts in some vaccines including MMR, IPV, and varicella; contact dermatitis (a Type IV hypersensitivity reaction) to these aminoglycosides is not a contraindication to vaccination, and anaphylaxis to these agents is extremely rare. Formaldehyde, used as an inactivating agent, is present in trace amounts well below the concentration that would be expected to cause allergic reactions. Thimerosal, an ethylmercury-based preservative, causes delayed-type (Type IV) hypersensitivity reactions in some individuals but is not a contraindication to vaccination; it has been removed from most childhood vaccine formulations.

<image>A reference table of common vaccine excipients and their allergenic potential. Organized as a matrix with rows for each excipient (gelatin, egg protein/ovalbumin, PEG, polysorbate 80, latex, yeast, neomycin, thimerosal) and columns showing: (1) Which vaccines contain this excipient (list of specific vaccines), (2) Type of allergic reaction it can cause (Type I IgE-mediated vs Type IV delayed), (3) Estimated frequency of allergic reactions, (4) How to evaluate (SPT, sIgE, graded challenge), (5) Management approach (avoid, observe, graded challenge, alternative vaccine). Highlighted boxes for key clinical scenarios: "Egg allergy + influenza vaccine = SAFE, no special precautions needed" and "PEG allergy + mRNA COVID vaccine = requires allergy evaluation." Cross-reactivity arrow connecting PEG and polysorbate 80.</image>

Approach to Suspected Vaccine Allergy

Risk Stratification

Proper risk stratification is essential for determining the appropriate evaluation and management pathway. Low-risk scenarios, in which standard vaccination can proceed without allergy evaluation, include local injection site reactions (redness, swelling, pain), vasovagal syncope, fever, malaise, and myalgia (which represent expected immune responses rather than allergic reactions), family history of vaccine reactions, egg allergy (for influenza and MMR vaccines), and known contact dermatitis to neomycin or thimerosal. Moderate-risk scenarios that warrant evaluation before revaccination include urticaria or angioedema occurring within four hours of vaccination and non-anaphylactic allergic reactions to a previous dose of the same vaccine. High-risk scenarios that require formal allergy evaluation include documented anaphylaxis to a previous dose of the same vaccine and known allergy to a specific vaccine component such as gelatin, PEG, polysorbate, or yeast.

Evaluation Protocol

The evaluation of suspected vaccine allergy begins with a detailed history documenting the timing and nature of the reaction, the specific vaccine and lot number if available, and concomitant medications that might have contributed to the event. The potential culprit component should be identified by reviewing the vaccine package insert for a complete list of excipients. Skin testing is then performed using a prick test with the full-strength vaccine followed, if negative, by intradermal testing with the vaccine at a 1:100 dilution. Individual excipient components can also be tested when available. Non-irritating concentrations have been established for many commonly used vaccines.

If skin testing is negative, a graded vaccine challenge can be performed. The standard two-step protocol involves administering 10% of the full vaccine dose, observing for 30 minutes, and then administering the remaining 90% followed by another 30-minute observation period. This procedure must be performed in a clinical setting with resuscitation equipment immediately available. When an alternative vaccine with a different excipient profile is available, this may be preferred over a graded challenge with the original formulation.

Immunization in the Immunocompromised

Live Vaccines Contraindicated in Immunocompromised Patients

General Principles (IDSA 2013 Guidelines, updated ACIP)

Several overarching principles govern vaccination decisions in immunocompromised patients. The most fundamental rule is that live vaccines are contraindicated in most significantly immunocompromised patients due to the risk of uncontrolled replication of the attenuated vaccine organism. Live vaccines include MMR, varicella, the now-discontinued live zoster vaccine (Zostavax), oral polio vaccine (OPV), BCG, yellow fever, oral typhoid, live attenuated influenza vaccine (LAIV/FluMist), rotavirus, and smallpox vaccine. Carefully defined exceptions exist for some mildly immunocompromised patients, such as HIV-positive individuals with CD4 counts of 200 or above who may receive MMR.

Inactivated, killed, subunit, and mRNA vaccines are safe to administer to immunocompromised patients. While the immunogenicity of these vaccines may be reduced, they are still recommended because even a suboptimal immune response may provide clinically meaningful protection. The degree of vaccine response depends on the nature and severity of the immunocompromise. The timing principle dictates that vaccination should occur when immune function is most intact: ideally at least 2 to 4 weeks before the initiation of immunosuppressive therapy, or after an appropriate interval following the discontinuation of immunosuppressive agents.

Household contacts of immunocompromised patients should be fully vaccinated, including with live vaccines, to provide indirect "cocooning" protection. The exceptions to this rule are oral polio vaccine, which should not be administered to household contacts due to the risk of vaccine virus shedding and transmission, and live attenuated influenza vaccine (LAIV), which should be avoided in household contacts of severely immunocompromised patients due to the possibility of transmission of the attenuated virus.

Specific Patient Populations

Primary Immunodeficiency

Vaccination approaches must be tailored to the specific type of primary immunodeficiency. Patients with severe combined immunodeficiency (SCID) must not receive any live vaccines; vaccination should be deferred until after successful HSCT and documentation of immune reconstitution. In X-linked agammaglobulinemia and other forms of agammaglobulinemia, live vaccines are contraindicated, with particular emphasis on avoiding oral polio vaccine due to the risk of vaccine-derived paralytic poliomyelitis. Inactivated vaccines may be administered but will elicit poor or absent responses in the absence of functional B cells; passive protection through IgG replacement therapy provides coverage against many vaccine-preventable diseases. CVID patients should avoid live vaccines, and inactivated vaccines are recommended with the understanding that responses may be suboptimal; annual influenza vaccination is expected to produce some protective response in many CVID patients, and pneumococcal vaccine responses may be used diagnostically to assess specific antibody function.

Chronic granulomatous disease represents an interesting exception: because CGD patients have intact T cell function, most live vaccines may be safely administered with the critical exception of live bacterial vaccines, particularly BCG, which poses a risk of disseminated infection. In partial DiGeorge syndrome, MMR and varicella vaccines may be administered if the CD4 count is 500 or above, the CD8 count is 200 or above, and mitogen proliferative responses are adequate. Complete DiGeorge syndrome, with its profound T cell deficiency, contraindicates all live vaccines until after thymus transplantation.

HIV/AIDS

Vaccination in HIV-positive patients is guided primarily by the CD4 T cell count. Patients with CD4 counts of 200 cells per microliter or above may receive MMR and varicella vaccines if they are susceptible. When the CD4 count falls below 200, all live vaccines should be avoided. All inactivated vaccines are recommended regardless of the CD4 count. Pneumococcal vaccination should follow the standard sequence with PCV20 or PCV15 followed by PPSV23, with revaccination per CDC guidelines. HPV vaccination follows the routine schedule and is particularly important given the increased risk of HPV-related malignancies in HIV-positive individuals. Hepatitis B vaccination may require a higher-dose schedule (40 micrograms) to achieve adequate seroprotection, and anti-HBs titers should be checked to confirm response. Annual inactivated influenza vaccine (not LAIV) is recommended. COVID-19 vaccination with mRNA vaccines is recommended for all eligible patients, with additional doses as indicated. Shingrix, the recombinant (non-live) zoster vaccine, is recommended for HIV-positive patients aged 19 years and older per ACIP 2024 guidelines.

Solid Organ Transplant (SOT)

The vaccination strategy for solid organ transplant recipients is divided into pre- and post-transplant phases. Before transplantation, all recommended vaccinations including live vaccines should be completed at least four weeks prior to the transplant procedure. After transplantation, live vaccines are permanently contraindicated due to lifelong immunosuppression. Inactivated vaccines should be deferred for at least 2 to 6 months post-transplant to allow for immune reconstitution and to reduce the theoretical risk of allograft rejection from immune stimulation. Responses to vaccines are reduced on immunosuppression, and additional doses may be necessary to achieve protective titers. Annual inactivated influenza vaccination is recommended. Pneumococcal vaccination follows standard recommendations. Hepatitis B titers should be checked, with revaccination using potentially higher doses if the patient is non-immune. COVID-19 vaccination is strongly recommended, though seroconversion rates after the initial two-dose mRNA series are reduced to approximately 30 to 60%, with improvement following booster doses.

HSCT Recipients

A unique feature of myeloablative HSCT is that all prior vaccine-induced immunity is ablated along with the recipient's hematopoietic system, necessitating complete revaccination as if the patient had never been immunized. The revaccination timeline for inactivated vaccines begins at 3 to 6 months post-transplant, with influenza vaccination initiated as early as 3 to 4 months. Live vaccines require a longer interval of at least 24 months post-HSCT and should only be administered once the patient is off immunosuppressive therapy and free of active graft-versus-host disease. MMR and varicella vaccines are deferred until at least 24 months post-transplant with confirmed adequate immune reconstitution. A complete three-dose primary series is required for most vaccines, as is standard for a previously unvaccinated individual. In patients receiving ongoing IgG replacement therapy, vaccine responses may be blunted by passively administered antibodies; timing of vaccination relative to IVIG infusions should be considered when feasible.

<image>A vaccination schedule reference chart for immunocompromised patients. Organized as a grid with patient populations across the top (PID - humoral, PID - cellular, HIV CD4>=200, HIV CD4<200, SOT pre-transplant, SOT post-transplant, HSCT). Down the left side: vaccine types (MMR, Varicella, Influenza - inactivated, Pneumococcal, Hepatitis B, HPV, Zoster - Shingrix, COVID-19, Tdap, Meningococcal). Each cell contains one of three icons: green checkmark (recommended/safe), red X (contraindicated), or yellow triangle (conditional - with specific criteria listed). Key footnotes at bottom explaining timing considerations: "Vaccinate >=2-4 weeks before starting immunosuppression," "Live vaccines >=24 months post-HSCT and off immunosuppression," "LAIV contraindicated in all immunocompromised patients." Special callout box: "Household contacts should receive all routine vaccines including live vaccines (except OPV)."</image>

Biologic Therapy-Specific Intervals

The timing of vaccination relative to biologic therapy requires agent-specific considerations. After rituximab, inactivated vaccines should be deferred for at least 6 months after the last dose, ideally until B cell recovery is documented; live vaccines should not be administered until B cells have fully recovered. During anti-TNF therapy, inactivated vaccines can be safely administered, but live vaccines require that the anti-TNF agent be held for at least 3 to 5 half-lives before administration. An important neonatal consideration is that infants born to mothers receiving anti-TNF biologics during pregnancy carry transplacentally transferred drug that persists for months after birth; live vaccines should therefore be avoided in these infants for the first 6 to 12 months of life. For patients on high-dose corticosteroids (20 mg or more of prednisone daily for two weeks or longer), live vaccines should be deferred until at least one month after discontinuation. Methotrexate should ideally be held for two weeks before and four weeks after live vaccine administration, though data are limited; inactivated vaccines are safe during methotrexate therapy. JAK inhibitors preclude the use of live vaccines during treatment, and while inactivated vaccines are safe, the immune response may be attenuated.

COVID-19 Vaccination in Immunocompromised

COVID-19 vaccination is recommended for all immunocompromised patients, with mRNA platforms (Pfizer-BioNTech, Moderna) preferred over other available formulations. An additional primary dose is recommended for immunocompromised individuals, establishing a three-dose primary series for mRNA vaccines. Booster doses should be administered per the ACIP schedule, and more frequent boosting may be warranted given the reduced magnitude and durability of immune responses. When available and feasible, monitoring of anti-spike antibody responses can help inform the need for additional doses, though assay standardization and interpretation remain imperfect. Tixagevimab/cilgavimab (Evusheld), a combination of two long-acting monoclonal antibodies, was authorized for pre-exposure prophylaxis in severely immunocompromised individuals who may not mount adequate responses to vaccination, though availability has varied with the evolution of circulating SARS-CoV-2 variants that may reduce antibody efficacy.

Key Clinical Pearls

• Egg allergy is NOT a contraindication to ANY influenza vaccine; no special precautions needed regardless of egg allergy severity
• MMR vaccine is grown in chick embryo fibroblasts and contains negligible egg protein; it is SAFE in egg-allergic patients
• Gelatin is the most commonly identified excipient allergen in vaccine anaphylaxis; test with gelatin SPT/sIgE if prior reaction to gelatin-containing vaccine
• PEG and polysorbate 80 are structurally related and can cross-react; evaluate if anaphylaxis to mRNA COVID vaccine
• Live vaccines are contraindicated in most significantly immunocompromised patients; Shingrix (recombinant zoster) is NOT a live vaccine and IS recommended in immunocompromised adults
• After HSCT, all prior vaccine immunity is lost; revaccinate starting at 3-6 months post-transplant (live vaccines >=24 months)
• Infants born to mothers on anti-TNF biologics should avoid live vaccines for the first 6-12 months due to transplacentally transferred drug
• Household contacts of immunocompromised patients should be fully vaccinated to provide cocooning protection

References

1. Kelso JM, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130(1):25-43.
2. Rubin LG, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-e100.
3. Turner PJ, et al. COVID-19 vaccine allergy: WHO/EAACI recommendations. Allergy. 2021;76(12):3599-3616.
4. Kroger A, et al. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). CDC. Updated 2023.
5. McNeil MM, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868-878.

Read this lecture as Markdown